ABPI collaborate with AHSN on NHS biomedical developments

The Association of the British Pharmaceutical Industry and Academic Health Science Network are to collaborate over a 5 year period on projects to accelerate and sustain biomedical innovations by the NHS. Top priorities are currently research, digital and artificial intelligence, genomics and personalised medicine, and medicines optimisation.
ABPI’s CEO Mike Thompson, said: “As a result of this new partnership, patients will be able to benefit from the innovative medicines and technologies of the future faster and more consistently. The prize for success will be a virtuous circle that delivers benefits for patients and the NHS. There will also be economic benefits to the UK from a thriving life sciences ecosystem. The NHS will benefit from improved signposting to relevant agencies and programmes where not directly provided by AHSNs.”
Mike Hannay, AHSN’s chair professor, said: “The establishment of the Innovation Exchange model, commissioned by the Office for Life Sciences, provides a step change opportunity to re-engineer a more effective industry interface. This, together with the ABPI partnership, will enable companies to benefit from a consistent offering from whichever AHSN they interact with. In turn, the NHS will benefit from better identification of products and services that can benefit patients and the health system, as well as improved signposting to relevant agencies and programmes where not directly provided by AHSNs.”